Animal trials of Bharat Biotech International Limited’s Covid-19 vaccine candidate, Covaxin, have been successful and the results showed the shot’s “remarkable immunogenicity and protective efficacy” in the Phase I clinical trials in India, the drugmaker has said.
“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” Bharat Biotech tweeted on Friday.
Bharat Biotech had received approval from the Central Drugs Standard Control Organisation to conduct the Phase-II trials earlier this month. It had announced in June that it successfully developed Covaxin in collaboration with ICMR and the National Institute of Virology (NIV).
As of now –
Total Coronavirus Cases: 4,663M
Total recovery: 3,624M
Total Death: 77,537
Lawcutor 